Absci Corporation
ABSI
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.5B
$8.82
▲ +0.23%
P/E
-11.03
Mkt Cap
$1.5B
52-Wk Range
$2.24–$12.06
52-Week Range
$2.24 - $12.06
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 251.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Integrated AI-driven drug discovery platform
- Unified drug development and cell line processes
- Advanced machine learning technologies
- Proprietary computational biology techniques
Bear Case
1 risk
- High volatility (beta 2.4). Larger-than-normal price swings expected.
Growth
Strong growth ahead
Increasing demand for AI in drug discovery
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+34.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ABSI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.18 vs -$0.19 consensus (+5.8% surprise). Revenue of $300.0K vs $919.6K expected (-67.4%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+5.8%
Revenue trend · last 8Q
—
+97%
+31%
-53%
-78%
-2%
-82%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.7M
$665.0K
$1.2M
$593.0K
$378.0K
$650.0K
$215.0K
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jun 25, 2026
vs Industry
How ABSI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related